Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Biotechnology

Healthcare
$4.48 -1.44%

-$0.12 today

Market cap
$283.23M
Beta
1.96
P/E (TTM)
-3.1
EPS (TTM)
-$2.59
52W Low $2.52High $13.67

Volume 1.05M

Average 0.94M

KYTX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Kyverna Therapeutics, Inc.NASDAQ: KYTX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $351K fell 29.9% year over year, behind the -23.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.6% from the prior quarter. Over 3 fiscal years it compounded at +19.6% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -29.9% toward the trailing-twelve-month pace of -23.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$351K-4.6% QoQ
Last fiscal yearDec 2025
$1.8M-15.7% YoY
LTMMar 2026
$1.65M-23.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.9%——
1 year-15.7%——
3-year CAGR+19.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
1.8M USD
Year-over-year change
-15.7%
4-year CAGR
+32.4%

Depreciation & Amortization vs competitors

How KYTX compares with its peers on the latest reported figures

  • KYTX's LTM Mar 2026 depreciation & amortization of $1.65M is the 6th largest of the 11 companies compared; the peer median is $1.75M.
  • Its year-over-year change of -23.4% is the 8th highest of 10, against a peer median of -1.7%.
  • Over three fiscal years its annual growth of +19.6% compares with a peer median of -3.5%.
KYTX Competitors Peer median
Depreciation & Amortization for KYTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1.25B +83349.3%+52.5%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$12.13M -8.0%-4.7%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$10.43M -42.2%-11.2%33645.2%
EDITEditas Medicine, Inc.LTM Mar 2026$4.17M -34.0%-5.9%10.8%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$1.99M -1.7%-30.8%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$1.65M -23.4%+19.6%—
CABACabaletta Bio, Inc.LTM Mar 2026$1.5M -16.9%+11.8%—
MREOMereo BioPharma Group plcLTM Mar 2026$1.18M +9.0%-11.2%236.0%
SLNSilence Therapeutics plcLTM Mar 2026$885K —-2.3%96.0%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$416K +0.0%+17.0%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$328K +19.3%-0.6%—
Peer median (excluding KYTX) $1.75M-1.7%-3.5%166.0%

Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.35M)(28.89M)(60.37M)(127.48M)(161.31M)
Depreciation & Amortization586K1.05M1.71M2.13M1.8M
Deferred Income Tax00000
Stock-Based Compensation7.25M929K2.22M8.36M10.08M
Change in Working Capital(4.49M)(10.33M)3.42M7.86M(1.08M)
Accounts Receivables00000
Inventory00000
Accounts Payables11K677K4.08M736K543K
Other Working Capital(4.5M)(11M)(659K)7.12M(1.62M)
Other Non-Cash Items850K1.13M605K(5.12M)(3.21M)
Operating Cash Flow(22.16M)(36.11M)(52.41M)(114.25M)(153.71M)
Capital Expenditures(1.29M)(768K)(621K)(2.21M)(5K)
Acquisitions (Net)000070K
Purchases of Investments0(56.5M)(54.85M)(490M)(364.62M)
Sales of Investments043.17M46.68M323.64M398.81M
Other Investing Activities0007.66M5.76M
Investing Cash Flow(1.29M)(14.1M)(8.79M)(160.9M)40.02M
Debt Repayment(41K)(249K)(781K)(956K)23.89M
Common Stock Issued000341.17M117.42M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities30K175K(1M)(3.1M)(144K)
Financing Cash Flow72.52M11.88M58.12M337.11M141.17M
Effect of Forex Changes00000
Net Change in Cash49.08M(38.33M)(3.08M)61.96M27.47M
Free Cash Flow(23.44M)(36.88M)(53.03M)(116.46M)(153.72M)

Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Intrinsic Alpha fair value

Locked

Current Price

$4.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.